Ivantis
Acquired
- Headquarters
- Irvine
- Founded
- 2007
- Business Model
- B2B
- Last Round
- Series CJan 2017
About
Ivantis was a medical device company developing the Hydrus Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower intraocular pressure in patients with primary open-angle glaucoma. The company's device received FDA clearance and was subsequently acquired by Alcon in January 2022 for $475 million.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free AccountInvestors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free Account